For pediatric patients 6 years of age and older with active psoriatic arthritis (PsA) or moderate to severe plaque psoriasis (Ps)[1]

SKYRIZI IS APPROVED FOR PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER[1]

Skyrizi®
risankizumab-rzaa

ONLY 4 DOSES A YEAR AFTER INITIATION DOSES AT WEEKS 0 & 4[1]

ONLY IL-23i APPROVED FOR Ps OR PsA IN PATIENTS AGES 6+ WEIGHING LESS THAN 40 kg[1]



Less than 40 kg: 55 mg/injection
single-dose prefilled syringe



Greater than or equal to 40 kg: 150 mg/injection
single-dose prefilled syringe or pen

INITIATION	MONTH 3	MONTH 6	MONTH 9	MONTH 12
WEEK 0 WEEK 4	WEEK 16	WEEK 28	WEEK 40	WEEK 52

RELIABLE 3-MONTH DOSING, ADMINISTERED BY A SINGLE SUBCUTANEOUS INJECTION[1]

PEDIATRIC ADMINISTRATION[1] INSTRUCTIONS: SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Caregivers may administer SKYRIZI to pediatric patients after training in subcutaneous injection technique. Provide proper training to caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.

For patients 10 to <18 years of age, it is recommended that SKYRIZI be administered by or under the supervision of an adult. For patients 6 to <10 years of age, SKYRIZI should be administered by an adult.

SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.[1]

IL-23i=interleukin-23 inhibitor.

INDICATIONS[1]

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older.

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.

SAFETY CONSIDERATIONS[1]

SKYRIZI is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of its excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately. SKYRIZI may increase the risk of infection. Instruct patients to report signs or symptoms of clinically important infection during treatment. Should such an infection occur, discontinue SKYRIZI until infection resolves. Evaluate patients for tuberculosis infection prior to initiating treatment with SKYRIZI. Avoid use of live vaccines in SKYRIZI patients.

Please see additional Important Safety Information on next page.
For more information, including Instructions for Use, please see accompanying full Prescribing Information.

INDICATIONS[1]

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older.
Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.

IMPORTANT SAFETY INFORMATION[1]

Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Immunizations

Avoid use of live vaccines in patients treated with SKYRIZI. Drugs that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, and a 55 mg/0.37 mL prefilled syringe.

Please see accompanying full Prescribing Information.

References: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
2. Data on file, AbbVie Inc. #1 IL biologic badge, 2025.



*"First-line" is defined as the first biologic prescription among patients who have not been prescribed biologics in the last 3 years.

†Source: IQVIA (NPA, NSP) and Symphony Health data through October 2025.

NPA=National Prescription Audit; NSP=National Sales Perspectives.

© 2026 AbbVie. All rights reserved.
SKYRIZI® and its design are registered trademarks of AbbVie Biotechnology Ltd.
US-SKZR-260138 October 2026

abbvie

Skyrizi®
risankizumab-rzaa